The Roche Group plans to discontinue research and early development of potential RNA interference (RNAi) therapeutics as part of a portfolio review designed to reduce costs. Its partner, Alnylam, said the decision wouldn’t impact its future plans. ---Subscribe to MedNous to access this article--- Company News Research & University News
